Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
6.47
+0.40 (6.59%)
At close: Jul 8, 2026, 4:00 PM EDT
6.06
-0.41 (-6.28%)
After-hours: Jul 8, 2026, 7:33 PM EDT
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 76 employees as of December 31, 2025. The number of employees increased by 5 or 7.04% compared to the previous year.
Employees
76
Change (1Y)
5
Growth (1Y)
7.04%
Revenue / Employee
$488,961
Profits / Employee
-$234,553
Market Cap
113.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | 5 | 7.04% |
| Dec 31, 2024 | 71 | -29 | -29.00% |
| Dec 31, 2023 | 100 | 78 | 354.55% |
| Dec 31, 2022 | 22 | -16 | -42.11% |
| Dec 31, 2021 | 38 | 9 | 31.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| Alps Group | 93 |
| Fortress Biotech | 78 |
| PolyPid | 75 |
| Biomea Fusion | 40 |
| Oncolytics Biotech | 29 |
| Cognition Therapeutics | 14 |
VRCA News
- 16 days ago - Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright - TheFly
- 7 weeks ago - Verrica Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 2 months ago - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c) - TheFly
- 2 months ago - Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts